Shopping Cart 0
Cart Subtotal
AED 0

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 7340

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 22020
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Pipeline Review, H2 2017, provides an overview of the Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline landscape.

Malignant peripheral nerve sheath tumors (MPNSTs) are sarcomas which originate from peripheral nerves or from cells associated with the nerve sheath, such as Schwann cells, perineural cells, or fibroblasts. Symptoms include lump or swelling in the in the soft tissue, numbness, burning or having that pins and needles feeling, weakness in the affected muscles and dizziness or loss of balance. Treatment includes surgery, radiotherapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 7, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology).

The pipeline guide reviews pipeline therapeutics for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Overview

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Companies Involved in Therapeutics Development

Bexion Pharmaceuticals LLC

Epizyme Inc

Madrigal Pharmaceuticals Inc.

Merck & Co Inc

Millennium Pharmaceuticals Inc

Novartis AG

Open Therapeutics LLC

Pfizer Inc

Plexxikon Inc

Vyriad Inc

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Drug Profiles

axitinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BXQ-350-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

everolimus-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ganetespib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nitrosylcobalamin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oncolytic Virus to Activate TIMP3 for Neuroblastoma and Malignant Peripheral Nerve Sheath Tumor-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oncolytic Virus to Target CD46 and SLC5A5 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pembrolizumab-Drug Profile

R&D Progress

pexidartinib hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sapanisertib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BRD4 for Malignant Peripheral Nerve Sheath Tumors-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tazemetostat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Product Development Milestones

Featured News & Press Releases

Dec 26, 2013: UTSW study identifies potential therapeutic target for incurable, rare type of soft-tissue cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Pipeline by Bexion Pharmaceuticals LLC, H2 2017

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Pipeline by Epizyme Inc, H2 2017

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Pipeline by Madrigal Pharmaceuticals Inc., H2 2017

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Pipeline by Merck & Co Inc, H2 2017

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Pipeline by Millennium Pharmaceuticals Inc, H2 2017

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Pipeline by Novartis AG, H2 2017

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Pipeline by Open Therapeutics LLC, H2 2017

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Pipeline by Pfizer Inc, H2 2017

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Pipeline by Plexxikon Inc, H2 2017

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Pipeline by Vyriad Inc, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Bexion Pharmaceuticals LLC

Epizyme Inc

Madrigal Pharmaceuticals Inc.

Merck & Co Inc

Millennium Pharmaceuticals Inc

Novartis AG

Open Therapeutics LLC

Pfizer Inc

Plexxikon Inc

Vyriad Inc

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Pipeline Review, H2 2017, provides an overview of the Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline landscape.

Malignant peripheral nerve sheath tumors (MPNSTs) are sarcomas which originate from peripheral nerves or from cells associated with the nerve sheath, such as Schwann cells, perineural cells, or fibroblasts. Symptoms include lump or swelling in the in the soft tissue, numbness, burning or having that pins and needles feeling, weakness in the affected muscles and dizziness or loss of balance. Treatment includes surgery, radiotherapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 7, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology).

The pipeline guide reviews pipeline therapeutics for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Overview

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Companies Involved in Therapeutics Development

Bexion Pharmaceuticals LLC

Epizyme Inc

Madrigal Pharmaceuticals Inc.

Merck & Co Inc

Millennium Pharmaceuticals Inc

Novartis AG

Open Therapeutics LLC

Pfizer Inc

Plexxikon Inc

Vyriad Inc

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Drug Profiles

axitinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BXQ-350-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

everolimus-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ganetespib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nitrosylcobalamin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oncolytic Virus to Activate TIMP3 for Neuroblastoma and Malignant Peripheral Nerve Sheath Tumor-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oncolytic Virus to Target CD46 and SLC5A5 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pembrolizumab-Drug Profile

R&D Progress

pexidartinib hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sapanisertib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BRD4 for Malignant Peripheral Nerve Sheath Tumors-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tazemetostat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Product Development Milestones

Featured News & Press Releases

Dec 26, 2013: UTSW study identifies potential therapeutic target for incurable, rare type of soft-tissue cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Pipeline by Bexion Pharmaceuticals LLC, H2 2017

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Pipeline by Epizyme Inc, H2 2017

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Pipeline by Madrigal Pharmaceuticals Inc., H2 2017

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Pipeline by Merck & Co Inc, H2 2017

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Pipeline by Millennium Pharmaceuticals Inc, H2 2017

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Pipeline by Novartis AG, H2 2017

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Pipeline by Open Therapeutics LLC, H2 2017

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Pipeline by Pfizer Inc, H2 2017

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Pipeline by Plexxikon Inc, H2 2017

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)-Pipeline by Vyriad Inc, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

Bexion Pharmaceuticals LLC

Epizyme Inc

Madrigal Pharmaceuticals Inc.

Merck & Co Inc

Millennium Pharmaceuticals Inc

Novartis AG

Open Therapeutics LLC

Pfizer Inc

Plexxikon Inc

Vyriad Inc